H1 FY17 revenue for EMIS Group, was up 1% compared to the same point last year, reaching £79.2m (H1 FY16: £78.6m), but adjusted operating profit fell 1% to £17.5m (H1 FY16: £17.7m). Recurring revenue now represents 84% of total revenue (up from 81% last year).
EMIS has substantially restructured its business in recent months (see EMIS delivers solid 2016 despite 'NHS headwinds'). Under new CEO Andy Thorburn (see EMIS names new CEO), reorganisation will continue in H2, but will focus more on getting the right skills into the business rather that cutting costs.
On a divisional level, Primary, Community & Acute Care revenue was down 3% to £58.5m (H1 FY16: £60.3m), but adjusted operating profit was up 5%. Within the division, Primary Care continues to hold a strong market share (56%), including more than a quarter of Clinical Commissioning Groups (CCGs) now using EMIS Web across all GPs in their region. EMIS also has a strong Child, Community & Mental Health presence in these CCGs. The more problematic area remains Accute Care, where challenging NHS funding has resulted in a reduction in non-recurring implementation work.
In Community Pharmacy, where EMIS holds 37% market share, revenue was up 5% to £10.9m. Its deal with Celesio UK, announced in March 2016, could see market share reach c.50% by the end of 2018. In Specialist & Care, revenue was up 19% to £8.4m and it has strengthened its position in outsourced diabetic eye screening and ophthalmology imaging services. Revenue from its Patient business was up 42% to £1.4m—it launched the new version of its Patient.info website last month.
It was a solid, if unspectacular, H1. The challenges of operating in the health sector remain, but its recurring revenue gives EMIS a solid foundation to weather ongoing financial headwinds. Its breadth of services across health and care also puts EMIS in a good position to benefit from increasing interest in joined-up care.